147 related articles for article (PubMed ID: 26421997)
1. Unpaid work in health economic evaluations.
Krol M; Brouwer W
Soc Sci Med; 2015 Nov; 144():127-37. PubMed ID: 26421997
[TBL] [Abstract][Full Text] [Related]
2. The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses.
Bouwmans C; Krol M; Severens H; Koopmanschap M; Brouwer W; Hakkaart-van Roijen L
Value Health; 2015 Sep; 18(6):753-8. PubMed ID: 26409601
[TBL] [Abstract][Full Text] [Related]
3. Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective.
Hubens K; Krol M; Coast J; Drummond MF; Brouwer WBF; Uyl-de Groot CA; Hakkaart-van Roijen L
Value Health; 2021 Nov; 24(11):1686-1699. PubMed ID: 34711370
[TBL] [Abstract][Full Text] [Related]
4. The Estimation and Inclusion of Presenteeism Costs in Applied Economic Evaluation: A Systematic Review.
Kigozi J; Jowett S; Lewis M; Barton P; Coast J
Value Health; 2017 Mar; 20(3):496-506. PubMed ID: 28292496
[TBL] [Abstract][Full Text] [Related]
5. The transferability of valuing lost productivity across jurisdictions. differences between national pharmacoeconomic guidelines.
Knies S; Severens JL; Ament AJ; Evers SM
Value Health; 2010 Aug; 13(5):519-27. PubMed ID: 20712601
[TBL] [Abstract][Full Text] [Related]
6. A noticeable difference? Productivity costs related to paid and unpaid work in economic evaluations on expensive drugs.
Krol M; Papenburg J; Tan SS; Brouwer W; Hakkaart L
Eur J Health Econ; 2016 May; 17(4):391-402. PubMed ID: 25876834
[TBL] [Abstract][Full Text] [Related]
7. Productivity costs in economic evaluations: past, present, future.
Krol M; Brouwer W; Rutten F
Pharmacoeconomics; 2013 Jul; 31(7):537-49. PubMed ID: 23620213
[TBL] [Abstract][Full Text] [Related]
8. How to estimate productivity costs in economic evaluations.
Krol M; Brouwer W
Pharmacoeconomics; 2014 Apr; 32(4):335-44. PubMed ID: 24504850
[TBL] [Abstract][Full Text] [Related]
9. Incorporating productivity loss in health economic evaluations: a review of guidelines and practices worldwide for research agenda in China.
Jiang S; Wang Y; Si L; Zang X; Gu YY; Jiang Y; Liu GG; Wu J
BMJ Glob Health; 2022 Aug; 7(8):. PubMed ID: 35977755
[TBL] [Abstract][Full Text] [Related]
10. Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire.
Zhang W; Bansback N; Kopec J; Anis AH
J Occup Environ Med; 2011 May; 53(5):530-6. PubMed ID: 21508868
[TBL] [Abstract][Full Text] [Related]
11. Time Is Money: Investigating the Value of Leisure Time and Unpaid Work.
Verbooy K; Hoefman R; van Exel J; Brouwer W
Value Health; 2018 Dec; 21(12):1428-1436. PubMed ID: 30502787
[TBL] [Abstract][Full Text] [Related]
12. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
13. Estimating productivity costs in health economic evaluations: a review of instruments and psychometric evidence.
Tang K
Pharmacoeconomics; 2015 Jan; 33(1):31-48. PubMed ID: 25169062
[TBL] [Abstract][Full Text] [Related]
14. CONCEPTUALIZATIONS OF THE SOCIETAL PERSPECTIVE WITHIN ECONOMIC EVALUATIONS: A SYSTEMATIC REVIEW.
Drost RMWA; van der Putten IM; Ruwaard D; Evers SMAA; Paulus ATG
Int J Technol Assess Health Care; 2017 Jan; 33(2):251-260. PubMed ID: 28641592
[TBL] [Abstract][Full Text] [Related]
15. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.
Zhang W; Bansback N; Guh D; Li X; Nosyk B; Marra CA; Anis AH
J Rheumatol; 2008 Sep; 35(9):1729-36. PubMed ID: 18688916
[TBL] [Abstract][Full Text] [Related]
16. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel.
Brouwer WB; Koopmanschap MA; Rutten FF
Health Econ; 1997; 6(3):253-9. PubMed ID: 9226143
[TBL] [Abstract][Full Text] [Related]
17. Hand osteoarthritis is associated with limitations in paid and unpaid work participation and related societal costs: the HOSTAS cohort.
Terpstra SES; van de Stadt L; Boonen A; Damman W; Rosendaal F; Kloppenburg M
RMD Open; 2022 Jul; 8(2):. PubMed ID: 35906024
[TBL] [Abstract][Full Text] [Related]
18. Productivity cost calculations in health economic evaluations: correcting for compensation mechanisms and multiplier effects.
Krol M; Brouwer WB; Severens JL; Kaper J; Evers SM
Soc Sci Med; 2012 Dec; 75(11):1981-8. PubMed ID: 22925428
[TBL] [Abstract][Full Text] [Related]
19. Indirect cost in economic evaluation: the opportunity cost of unpaid inputs.
Posnett J; Jan S
Health Econ; 1996; 5(1):13-23. PubMed ID: 8653189
[TBL] [Abstract][Full Text] [Related]
20. Development of a matrix of cost domains in economic evaluation of rheumatoid arthritis.
Merkesdal S; Ruof J; Huelsemann JL; Schoeffski O; Maetzel A; Mau W; Zeidler H
J Rheumatol; 2001 Mar; 28(3):657-61. PubMed ID: 11296977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
